New Vernon Capital Holdings II’s Gilead Sciences GILD Stock Holding History

New Vernon Capital Holdings II’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-343	Closed	-$23.5K	–	74
2024 Q2	$23.5K	Hold	343	–	–	0.01%	72
2024 Q1	$25.1K	Buy	+343	New	+$26.4K	0.01%	75
2023 Q3	–	Sell	-1,131	Closed	-$87.2K	–	69
2023 Q2	$87.2K	Sell	1,131 -2,288	-67%	-$182K	0.06%	69
2023 Q1	$284K	Hold	3,419	–	–	0.21%	32
2022 Q4	$294K	Hold	3,419	–	–	0.24%	24
2022 Q3	$211K	Sell	3,419 -2,300	-40%	-$145K	0.22%	22
2022 Q2	$353K	Buy	+5,719	New	+$354K	0.28%	20
2019 Q1	–	Sell	-5,071	Closed	-$317K	–	25
2018 Q4	$317K	Buy	5,071 +1,349	+36%	+$94.3K	0.49%	27
2018 Q3	$287K	Buy	3,722 +18	+0.5%	+$1.36K	0.3%	32
2018 Q2	$262K	Buy	+3,704	New	+$262K	0.29%	33

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

New Vernon Capital Holdings II's GILD Position: Q3 2024 in Review

New Vernon Capital Holdings II sold out of Gilead Sciences (GILD) in Q3 2024, closing a stake of 343 shares — an estimated $23.5K sold.

New Vernon Capital Holdings II first reported a position in GILD in Q2 2018 and held it in 10 quarters. The position peaked at $353K in Q2 2022. 1,719 funds tracked by Wall St. Rank hold GILD as of Q3 2024.

New Vernon Capital Holdings II reported no remaining Gilead Sciences position as of Q3 2024 after selling out during the quarter.
New Vernon Capital Holdings II sold 343 Gilead Sciences shares in Q3 2024, an estimated $23.5K.
New Vernon Capital Holdings II first reported a position in Gilead Sciences in Q2 2018 and held it in 10 quarters.
New Vernon Capital Holdings II's Gilead Sciences position peaked at $353K in Q2 2022.
1,719 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2024.

Based on New Vernon Capital Holdings II's 13F filing for Q3 2024, filed 14 Nov 2024.